Julien Torgue

Julien Torgue has been the Chief Scientific Officer (CSO) of Orano Med since 2010. His career started as a Project Manager at Goodwin Biotechnology, where he oversaw the development, production and preparation of CMC (Chemistry, Manufacturing, and Controls) documentation for antibodies intended for clinical trials. In 2010, he joined Orano Med as CSO. In this role, he was tasked with filing an IND for the first in human use of lead-212, which was submitted to the FDA in December 2010, managing the clinical trials that followed and multiple other scientific partnerships with academic and industrial partners. Over the years, he has played a key role in the strategic development of the company and continues to oversee Orano Med research programs and external collaborations, while driving the ramp-up of Orano Med's activities. 

Julien Torgue, Ph.D., graduated from Florida Institute of Technology with a B.S. in Biochemistry, and a Ph.D. in Biology.